Health
Virus drug benefit only marginal: study – Tenterfield Star
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly short…
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
Noosa News23 hours agoFuel tanker driver killed in horror head-on crash near Blackbutt identified as beloved father-of-two
-
General17 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
Noosa News22 hours agoPalestine protesters forced into last-minute reroute
-
Business21 hours agoUp 20% in 2 days, are Codan shares a buy, hold or sell?